Shenzhen, China, March 27, 2023 - MGI and Berry Oncology Co., Ltd. (hereinafter referred to as "Berry Oncology") officially signed a strategic cooperation agreement. MGI will provide the DNBSEQ sequencing platform and automation systems to support Berry Oncology in early cancer screening as well as registration and declaration of drug concomitant testing products, aiming at accelerating the high-quality development of precision cancer diagnosis and treatment.

"We are excited to partner with MGI to facilitate deeper, broader, and more sustainable technology and product innovation in early cancer screening. This cooperation will be a successful integration of best-in-class technology and platforms in our respective fields to jointly advance the development of precision cancer diagnosis and treatment so that our products and technology will serve the people and benefit the world." Said Zhou Jun, CEO of Berry Oncology.

"As a leading provider of life science core tools and technology, MGI is committed to providing an open and cooperative ecosystem to midstream and downstream clinical and scientific research users. Over the past six years, we have developed a full range of sequencing products across low, medium, and high throughputs, and lowered the sequencing cost to less than USD 100. We are looking forward to joining hands with Berry Oncology to reach our full potential for win-win development and seek more profound and comprehensive breakthroughs in oncology and precision medicine and facilitate the arrival of the human genome era." Said Mu Feng, CEO of MGI.

Currently, high-throughput sequencing technology has been maturely applied in early cancer and multi-cancer screening. As one of two companies in the world that can independently develop and mass-produce low-, medium- and high-throughput clinical gene sequencers from GB to TB, MGI has developed an extensive product portfolio to accommodate different applications with high-quality data output and low cost. Berry Oncology is a global leading player in genetic detection and early screening of cancer. The cooperation between the two parties will help build a full-cycle core product pipeline for precision cancer diagnosis and treatment and continue to optimize the delivery and accessibility of effective cancer screening services.